nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Irritability—Imiquimod—skin cancer	0.0456	0.0456	CcSEcCtD
Metaxalone—Pruritus—Vismodegib—skin cancer	0.0316	0.0316	CcSEcCtD
Metaxalone—Vomiting—Vismodegib—skin cancer	0.0284	0.0284	CcSEcCtD
Metaxalone—Rash—Vismodegib—skin cancer	0.0281	0.0281	CcSEcCtD
Metaxalone—Dermatitis—Vismodegib—skin cancer	0.0281	0.0281	CcSEcCtD
Metaxalone—Anaphylactic shock—Vemurafenib—skin cancer	0.0276	0.0276	CcSEcCtD
Metaxalone—Nausea—Vismodegib—skin cancer	0.0265	0.0265	CcSEcCtD
Metaxalone—Irritability—Fluorouracil—skin cancer	0.0252	0.0252	CcSEcCtD
Metaxalone—Somnolence—Imiquimod—skin cancer	0.0209	0.0209	CcSEcCtD
Metaxalone—Hypersensitivity—Vemurafenib—skin cancer	0.0203	0.0203	CcSEcCtD
Metaxalone—Pruritus—Vemurafenib—skin cancer	0.0195	0.0195	CcSEcCtD
Metaxalone—Leukopenia—Bleomycin—skin cancer	0.0183	0.0183	CcSEcCtD
Metaxalone—Dizziness—Vemurafenib—skin cancer	0.0182	0.0182	CcSEcCtD
Metaxalone—Vomiting—Vemurafenib—skin cancer	0.0175	0.0175	CcSEcCtD
Metaxalone—Rash—Vemurafenib—skin cancer	0.0174	0.0174	CcSEcCtD
Metaxalone—Dermatitis—Vemurafenib—skin cancer	0.0174	0.0174	CcSEcCtD
Metaxalone—Hypersensitivity—Imiquimod—skin cancer	0.0173	0.0173	CcSEcCtD
Metaxalone—Headache—Vemurafenib—skin cancer	0.0173	0.0173	CcSEcCtD
Metaxalone—Leukopenia—Dactinomycin—skin cancer	0.0171	0.0171	CcSEcCtD
Metaxalone—Anaphylactic shock—Bleomycin—skin cancer	0.0167	0.0167	CcSEcCtD
Metaxalone—Pruritus—Imiquimod—skin cancer	0.0166	0.0166	CcSEcCtD
Metaxalone—Nausea—Vemurafenib—skin cancer	0.0164	0.0164	CcSEcCtD
Metaxalone—Dizziness—Imiquimod—skin cancer	0.0155	0.0155	CcSEcCtD
Metaxalone—Leukopenia—Temozolomide—skin cancer	0.0154	0.0154	CcSEcCtD
Metaxalone—Vomiting—Imiquimod—skin cancer	0.0149	0.0149	CcSEcCtD
Metaxalone—Rash—Imiquimod—skin cancer	0.0148	0.0148	CcSEcCtD
Metaxalone—Dermatitis—Imiquimod—skin cancer	0.0148	0.0148	CcSEcCtD
Metaxalone—Headache—Imiquimod—skin cancer	0.0147	0.0147	CcSEcCtD
Metaxalone—Jaundice—Docetaxel—skin cancer	0.0143	0.0143	CcSEcCtD
Metaxalone—Leukopenia—Fluorouracil—skin cancer	0.0142	0.0142	CcSEcCtD
Metaxalone—Anaphylactic shock—Temozolomide—skin cancer	0.0141	0.0141	CcSEcCtD
Metaxalone—Nausea—Imiquimod—skin cancer	0.014	0.014	CcSEcCtD
Metaxalone—Anaphylactic shock—Fluorouracil—skin cancer	0.013	0.013	CcSEcCtD
Metaxalone—Somnolence—Temozolomide—skin cancer	0.0125	0.0125	CcSEcCtD
Metaxalone—Hypersensitivity—Bleomycin—skin cancer	0.0123	0.0123	CcSEcCtD
Metaxalone—Pruritus—Bleomycin—skin cancer	0.0118	0.0118	CcSEcCtD
Metaxalone—Somnolence—Fluorouracil—skin cancer	0.0115	0.0115	CcSEcCtD
Metaxalone—Hypersensitivity—Dactinomycin—skin cancer	0.0115	0.0115	CcSEcCtD
Metaxalone—Vomiting—Bleomycin—skin cancer	0.0106	0.0106	CcSEcCtD
Metaxalone—Rash—Bleomycin—skin cancer	0.0105	0.0105	CcSEcCtD
Metaxalone—Dermatitis—Bleomycin—skin cancer	0.0105	0.0105	CcSEcCtD
Metaxalone—Hypersensitivity—Temozolomide—skin cancer	0.0104	0.0104	CcSEcCtD
Metaxalone—Leukopenia—Docetaxel—skin cancer	0.0103	0.0103	CcSEcCtD
Metaxalone—Pruritus—Temozolomide—skin cancer	0.00996	0.00996	CcSEcCtD
Metaxalone—Nausea—Bleomycin—skin cancer	0.00992	0.00992	CcSEcCtD
Metaxalone—Vomiting—Dactinomycin—skin cancer	0.0099	0.0099	CcSEcCtD
Metaxalone—Rash—Dactinomycin—skin cancer	0.00982	0.00982	CcSEcCtD
Metaxalone—Hypersensitivity—Fluorouracil—skin cancer	0.00956	0.00956	CcSEcCtD
Metaxalone—Anaphylactic shock—Docetaxel—skin cancer	0.00937	0.00937	CcSEcCtD
Metaxalone—Dizziness—Temozolomide—skin cancer	0.00931	0.00931	CcSEcCtD
Metaxalone—Nausea—Dactinomycin—skin cancer	0.00925	0.00925	CcSEcCtD
Metaxalone—Pruritus—Fluorouracil—skin cancer	0.00918	0.00918	CcSEcCtD
Metaxalone—Vomiting—Temozolomide—skin cancer	0.00895	0.00895	CcSEcCtD
Metaxalone—Rash—Temozolomide—skin cancer	0.00888	0.00888	CcSEcCtD
Metaxalone—Dermatitis—Temozolomide—skin cancer	0.00887	0.00887	CcSEcCtD
Metaxalone—Headache—Temozolomide—skin cancer	0.00882	0.00882	CcSEcCtD
Metaxalone—Dizziness—Fluorouracil—skin cancer	0.00858	0.00858	CcSEcCtD
Metaxalone—Nausea—Temozolomide—skin cancer	0.00836	0.00836	CcSEcCtD
Metaxalone—Somnolence—Docetaxel—skin cancer	0.00833	0.00833	CcSEcCtD
Metaxalone—Vomiting—Fluorouracil—skin cancer	0.00825	0.00825	CcSEcCtD
Metaxalone—Rash—Fluorouracil—skin cancer	0.00818	0.00818	CcSEcCtD
Metaxalone—Dermatitis—Fluorouracil—skin cancer	0.00817	0.00817	CcSEcCtD
Metaxalone—Headache—Fluorouracil—skin cancer	0.00813	0.00813	CcSEcCtD
Metaxalone—Nausea—Fluorouracil—skin cancer	0.00771	0.00771	CcSEcCtD
Metaxalone—Hypersensitivity—Docetaxel—skin cancer	0.0069	0.0069	CcSEcCtD
Metaxalone—Pruritus—Docetaxel—skin cancer	0.00663	0.00663	CcSEcCtD
Metaxalone—Dizziness—Docetaxel—skin cancer	0.00619	0.00619	CcSEcCtD
Metaxalone—Vomiting—Docetaxel—skin cancer	0.00595	0.00595	CcSEcCtD
Metaxalone—Rash—Docetaxel—skin cancer	0.0059	0.0059	CcSEcCtD
Metaxalone—Dermatitis—Docetaxel—skin cancer	0.0059	0.0059	CcSEcCtD
Metaxalone—Headache—Docetaxel—skin cancer	0.00587	0.00587	CcSEcCtD
Metaxalone—Nausea—Docetaxel—skin cancer	0.00556	0.00556	CcSEcCtD
